Latest news with #ASPN
Business Insider
4 days ago
- Business
- Business Insider
Canaccord Genuity Sticks to Its Buy Rating for Aspen Aerogels (ASPN)
In a report released today, George Gianarikas from Canaccord Genuity maintained a Buy rating on Aspen Aerogels, with a price target of $10.00. The company's shares closed today at $7.57. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Gianarikas covers the Industrials sector, focusing on stocks such as Surf Air Mobility, Inc., NuScale Power, and Enovix. According to TipRanks, Gianarikas has an average return of 9.6% and a 41.67% success rate on recommended stocks. In addition to Canaccord Genuity, Aspen Aerogels also received a Buy from Craig-Hallum's Eric Stine in a report issued on August 5. However, on July 24, TR | OpenAI – 4o reiterated a Hold rating on Aspen Aerogels (NYSE: ASPN). ASPN market cap is currently $678.8M and has a P/E ratio of -2.36. Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ASPN in relation to earlier this year.
Reuters
29-07-2025
- Business
- Reuters
India's Asian Paints meets first-quarter profit view
July 29 (Reuters) - Asian Paints ( opens new tab, India's largest paint-maker by market share, reported first-quarter profit in-line with market expectations on Tuesday. Consolidated net profit came in at 11 billion rupees ($126.7 million) in the reported quarter. Analysts, on an average, were expecting a profit of 11.08 billion rupees, per data compiled by LSEG. Shares of the company turned positive after results and were last trading 2% higher. ($1 = 86.8310 Indian rupees)
Yahoo
18-07-2025
- Health
- Yahoo
TerSera Therapeutics to Present Real-World Data on Intrathecal Ziconotide (PRIALT®) Prescription Patterns at ASPN 2025
DEERFIELD, Ill., July 18, 2025--(BUSINESS WIRE)--TerSera Therapeutics LLC, a biopharmaceutical company with a focus in oncology, rare disease, and non-opioid pain management, announced today that its collaborative research on intrathecal ziconotide (PRIALT®) prescribing patterns has been accepted for presentation at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN) taking place July 17-20, 2025, in Miami, Florida. The poster will be presented by the primary author, Tolga Suvar, M.D., Assistant Professor, Department of Anesthesiology and Pain Medicine, and Attending Physician at Rush University Pain Center in Chicago, IL. A copy of the poster is available here. The abstract, titled "Real-world Treatment Patterns of Intrathecal Ziconotide", highlights a retrospective, non-interventional study conducted in partnership with Pentec Health, Inc., and other clinical collaborators. The study analyzed real-world data from over 1,000 patients treated with ziconotide between 2017 and 2024, using dispensing and claims records from Pentec, a leading provider of specialty infusion pharmacy and complex in-home clinical services. Evolution of prescribing patterns was analyzed over time and compared with the recommendations for ziconotide in the Polyanalgesic Consensus Conference (PACC) guidelines. Key findings from the study1 include: Shift Toward Monotherapy Use: Use of ziconotide as monotherapy increased from 36.0% in 2017–2018 to 63.1% in 2023–2024, reflecting growing adoption of guideline-aligned prescribing of ziconotide. Lower Starting Doses: The proportion of patients initiated on lower ziconotide doses (<0.5 mcg/day) rose from 3.4% to 20.3% over the study period, indicating a trend toward more conservative initial dosing strategies. Increased Use of Patient-Controlled Analgesia (PCA): The use of basal rate with PCA nearly doubled, from 23.7% to 45.3% over the study period, suggesting increasing use of novel approaches to delivery of intrathecal medications. "These findings underscore the importance of real-world evidence in shaping clinical practice," said Dr. Suvar. "It is encouraging to see increased alignment with PACC guidelines and a growing emphasis on patient-tailored dosing strategies. Precision in dosing—based on the unique characteristics and pathologies of each patient—is essential for optimizing outcomes and minimizing risk." About PRIALT® (Ziconotide Intrathecal Infusion)PRIALT is a non-opioid intrathecal analgesic indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatments. Derived from a marine snail peptide, ziconotide acts as a selective N-type calcium channel blocker, interrupting pain signal transmission in the spinal cord. Ziconotide is administered via continuous intrathecal infusion and is not associated with the risk of addiction or respiratory depression commonly seen with opioid therapies.2 IMPORTANT SAFETY INFORMATION WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS PRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms. ContraindicationsPRIALT is contraindicated in patients with: A known hypersensitivity to ziconotide or any of its formulation components. Any other concomitant treatment or medical condition that would render intrathecal administration hazardous, such as the presence of infection at the microinfusion injection site, uncontrolled bleeding diathesis, and spinal canal obstruction that impairs circulation of cerebrospinal fluid (CSF). A pre-existing history of psychosis. Warnings and PrecautionsCognitive and Neuropsychiatric Adverse ReactionsSevere psychiatric symptoms and neurological impairment may occur during treatment. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. PRIALT may cause or worsen depression, with the risk of suicide in susceptible patients. In clinical trials, 12% of patients reported hallucinations; other acute psychiatric events included paranoid reactions (3%), hostility (2%), delirium (2%), psychosis (1%), and manic reactions (0.4%). Patients with pretreatment psychiatric disorders may be at an increased risk. Management of psychiatric complications may need to include discontinuation of PRIALT, treatment with psychotherapeutic agents and/or short-term hospitalization. In clinical trials, cognitive adverse reactions included confusion (33%), memory impairment (22%), speech disorder (14%), aphasia (12%), thinking abnormal (8%), and amnesia (1%). Cognitive impairment may appear gradually after several weeks of treatment. Reduce the dose of PRIALT or discontinue the use of PRIALT if signs or symptoms of cognitive impairment develop, but other contributing causes must also be considered. The cognitive effects of PRIALT are generally reversible within 2 weeks after drug discontinuation. The elderly (≥65 years) are at higher risk for confusion. Concomitant use of central nervous system (CNS) depressants with PRIALT may have additive effects. Meningitis and Other InfectionsMeningitis can occur due to inadvertent contamination of the microinfusion device and other means. In clinical trials, the rate of meningitis was 3% (40 cases) in the PRIALT group using either internal or external microinfusion devices and 1% (1 case) with placebo. In patients with external microinfusion devices and catheters, meningitis occurred in 38 out of 41 patients (93%), 37 of whom received PRIALT and one who received placebo. Patients, caregivers, and healthcare providers must be particularly vigilant for the signs and symptoms of meningitis including, but not limited to, fever, headache, stiff neck, altered mental status (e.g., lethargy, confusion, disorientation), nausea or vomiting, and occasionally seizures. Strict aseptic procedures must be used during the preparation of the PRIALT solution and refilling of the microinfusion device. Reduced Level of ConsciousnessIn clinical trials, 2% of PRIALT-treated patients became unresponsive or stuporous. If reduced levels of consciousness occur, discontinue PRIALT until the event resolves, and other etiologies (e.g., meningitis) must be considered. Elevation of Serum Creatine KinaseIn clinical trials, serum creatine kinase (CK) levels above the upper limit of normal (ULN) were reported in 40% of patients, with 11% of patients having CK levels >3 times ULN. Incidences were higher during the first 2 months of treatment. Serum CK should be monitored periodically. In the setting of new neuromuscular symptoms, evaluate patients, obtain CK measurements, and if symptoms continue and CK levels remain elevated or continue to rise, reduce the dose or discontinue the use of PRIALT. Withdrawal From OpiatesPRIALT is not an opiate and cannot prevent or relieve the symptoms associated with the withdrawal of opiates. To avoid withdrawal syndrome when opiate withdrawal is necessary, do not abruptly reduce or withdraw opioid medications. Driving and Operating MachineryUse of PRIALT has been associated with cognitive impairment and decreased alertness/unresponsiveness. Caution patients against engaging in hazardous activities that require complete mental alertness or motor coordination. Most Common Adverse ReactionsThe most frequently reported adverse reactions (≥25%) in clinical trials (n=1254 PRIALT-treated patients) were dizziness, nausea, confusional state, and nystagmus. Slower titration of PRIALT may result in fewer serious adverse reactions and discontinuations for adverse reactions. IndicationPRIALT® (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine. To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or You may also contact TerSera Therapeutics at 1-844-334- 4035 or medicalinformation@ Please see full Prescribing Information, including BOXED Warning. About TerSera TherapeuticsTerSera Therapeutics is a biopharmaceutical company with a focus in oncology, rare disease, and non-opioid pain management. Founded in 2016, TerSera is building new cornerstones of care through its portfolio of unique therapeutics, amplifying their ability to deliver meaningful outcomes for patients. For additional information, please visit and follow us on LinkedIn. About Pentec HealthPentec Health is a leader in specialty pharmacy, infusion services, and DME distribution, committed to solving and simplifying complex care challenges to better meet patient and provider needs. Accredited by the Joint Commission and the American Nurses Credentialing Center, with distinctions in Specialty Care Nurse Fellowship, Pentec Health delivers exceptional results through unique solutions, technical expertise, and clinical collaboration. Our proven delivery models reduce administrative burdens and help improve patient outcomes. Pentec Health serves more than 11,000 patients living with complex medical conditions, with care provided nationwide by over 350 clinicians. For additional information, please visit References Suvar, T., Lindley, D., Leatherman, D., Howard, K., Lucia, R., Duran, N., Murray, M., McGlothlen, G., Dagenhart, J., Cannon, J., Sayeed, S., & Lubenow, T. (2025, July). Real-world treatment patterns of intrathecal ziconotide [Poster presentation]. American Society of Pain and Neuroscience (ASPN) 2025 Annual Meeting. PRIALT® (ziconotide). Prescribing information. TerSera Therapeutics LLC. PRIALT is a registered trademark of TerSera Therapeutics LLC. TerSera and the TerSera logo are trademarks of TerSera Therapeutics LLC. ©2025 TerSera Therapeutics LLC. All rights reserved. View source version on Contacts For more information: TerSera Therapeutics: Mark Leonard847-651-9682mleonard@ Pentec Health: Jeremy Sign in to access your portfolio
Business Upturn
15-07-2025
- Business
- Business Upturn
Aurora Spine Announces Participation in 7th Annual American Society of Pain & Neuroscience Conference
CARLSBAD, California, July 15, 2025 (GLOBE NEWSWIRE) — Aurora Spine Corporation ('Aurora Spine' or the 'Company') (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced it will be participating in the 7th Annual ASPN Conference sponsored by The American Society of Pain Neuroscience (ASPN) to be held July 17-20 at the Fontainebleu Miami Hotel in Miami Beach, Florida. Aurora will be located at Booth 129/130. To kick off the first full day of the conference (July 18th), there will be a series of discussions starting with a General Session on 'Embracing Disruption, Driving Innovation. Minimally Invasive Spine.' Within this General Session, there will be two discussions with relevancy to Aurora Spine products: Surgical Approaches to Facet Disease and Posterior Approaches to Lumbar Spine and SI Joint. On Saturday, July 19th, Aurora's ZIP product series will be highlighted in an ASPN Top Abstract discussion, of which only 12 are selected out of 330 papers that were submitted. Steven Falowski, MD, will deliver the podium talk to discuss: Functional Outcomes in the Low Back Pain Subject with a Novel Interspinous Fusion Device: REFINE Study 12 Month Results. Later that day, Aurora Spine will be sponsoring the ASPN Charity Reception with beneficiaries being the IRONMAN Foundation and Return to Duty. 'We are very excited about this year's ASPN Conference, especially having been selected for a podium talk that highlights our ZIP series of products. We are extremely honored to be selected for this discussion, as there are only a few spots for selection,' said Trent Northcutt, President and CEO of Aurora Spine. 'We are also excited about this year's ASPN Conference as we'll be introducing our AERO Lumbar Fusion System to industry professionals in attendance, which will include in excess of 3,000 industry professionals including neuro, ortho and pain interventionalists.' For more information about the conference go to: ASPN Annual Conference July 2025 . About Aurora Spine Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of proprietary, minimally invasive, and regenerative technologies. The company is committed to improving surgical outcomes through innovation, efficiency, and patient-centered design. For more information, visit: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, many of which are beyond Aurora Spine's control. Forward-looking statements include, but are not limited to, statements regarding the expected use and success of the Company's products, including the AERO Lumbar Fusion System. Actual results may differ materially. Please refer to Aurora Spine's final prospectus and public filings for additional information on risks and uncertainties. These forward-looking statements speak only as of the date of this release. Aurora Spine undertakes no obligation to revise or update them to reflect future events or circumstances.
Yahoo
10-07-2025
- Health
- Yahoo
Pelthos Therapeutics Launches ZELSUVMI™ (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum
ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies Once-daily topical prescription medication can be applied by patients, parents and caregivers outside of a physician's office, at home or on the go Molluscum contagiosum is a highly contagious viral skin condition that afflicts an estimated 16.7 million people with up to 6 million new incidents per year in the United States, most of them children DURHAM, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the launch of ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i,ii ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections, a highly contagious viral skin condition. 'We believe that the commercial launch of ZELSUVMI marks a significant advancement for patients with molluscum and their caregivers, who previously lacked an at-home treatment option for this burdensome skin infection,' said Scott Plesha, CEO of Pelthos. 'We are excited to make ZELSUVMI widely available for the millions of patients afflicted by this condition. Our commercial efforts will aim to provide stellar education and support for patients seeking effective treatment for their molluscum infections.' ZELSUVMI is a novel, topical nitric oxide-releasing gel for the treatment of molluscum at the time of diagnosis. The once-daily prescription medication is effective, well tolerated, and convenient for at-home or on-the-go application and can be used to treat infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI was studied in the largest randomized clinical trial for the treatment of molluscum. The trial was a multicenter, randomized, double-blind, vehicle controlled, parallel-group, Phase 3 study of the efficacy and safety of ZELSUVMI in 891 patients. Complete clearance of molluscum lesions was seen in nearly 33% of patients compared with 19.7% of patients who did not receive the active ingredient at the twelfth week. For many patients, ZELSUVMI demonstrated results within two weeks.i,ii "Many parents delay seeking treatment for their children's uncomfortable lesions because current procedural treatments and frequent office visits can be inconvenient, while therapeutic options are limited. Untreated molluscum can spread throughout the child's body but also to other family members," said Nanette Silverberg, MD, Chief of Pediatric Dermatology at the Mount Sinai Health System. 'A safe and effective topical gel for molluscum, like ZELSUVMI, which can be applied at home or on the go, would make a significant difference for this young patient population and address a serious, unmet medical need." "We are launching our ZelsuvmiGo patient support program, which we expect to help onboard patients seamlessly and provide resources for caregivers," said Sai Rangarao, Chief Commercial Officer at Pelthos. "To ensure that ZELSUVMI reaches the people who need it quickly, we have hired 50 sales territory managers across the country to work with physicians who treat a high volume of patients with molluscum. We have also implemented extensive digital outreach and awareness efforts to ensure ZELSUVMI can be prescribed by any healthcare provider at any time. These patients have waited a long time for an at-home treatment option." ZELSUVMI is now commercially available through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies via prescription. For more information about ZELSUVMI visit About Molluscum ContagiosumMolluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. This highly contagious viral skin condition afflicts an estimated 16.7 million people, with up to 6 million new incidents every year in the United States, most of them children.i,ii,iii Individuals with compromised immune systems are at an elevated risk of contracting molluscum, with the condition impacting approximately 20% of HIV Molluscum infections spread to others through contact with infected persons or contaminated objects like towels, toys, furniture, swimming pools, and other surfaces. Molluscum infections present with raised, flesh-colored or red bumps that can appear anywhere on the body, including the face, hands, trunk, genitals, back of the knees, armpits, and other sensitive areas. People with molluscum may suffer discomfort from itching, secondary bacterial infections from scratching, or atopic dermatitis, as well as immense social stigma from having visible molluscum lesions that may persist for months to years. It is estimated that 30% of children will have lesions that persist beyond 18 months.v Up to 73% of children with molluscum go About ZELSUVMI™ (berdazimer) topical gel, 10.3%ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI received a novel drug designation from the U.S. Food and Drug Administration in 2024 and is the first and only approved topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician's office, or other medical setting to treat this highly contagious viral skin infection. The product was developed using the proprietary nitric oxide-based technology platform, NITRICIL™, now owned by Ligand Pharmaceuticals Incorporated. Complete prescribing information and important safety information is available at IMPORTANT SAFETY INFORMATION Contraindications: None. Warnings: Application site reactions, including, allergic contact dermatitis occurred. Discontinue ZELSUVMI and initiate appropriate therapy. Adverse Reactions: The most commonly reported adverse reactions (≥1%) are application site reactions including pain such as burning or stinging sensations (18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%). About Pelthos TherapeuticsPelthos Therapeutics (NYSE American: PTHS) is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company's lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at Follow Pelthos on LinkedIn and X. Forward-Looking StatementsThis press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos' current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as 'plans,' 'believes,' 'expects,' 'anticipates,' and 'will,' and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) our belief that the commercial launch of ZELSUVMI marks a significant advancement for patients with molluscum and their caregivers, (ii) our commercial efforts will aim to provide stellar education and support for patients seeking effective treatment for their molluscum infections, (iii) our expectation that the launch of ZelsuvmiGo patient support program will help onboard patients seamlessly and provide resources for caregivers; and (iv) the timing of product launches, including ZELSUVMI. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law. Contacts Media:KWM CommunicationsKellie Walsh / Rachel Kesslerpelthos@ (914) 315-6072 Investors:LifeSci Advisors, LLCMike Moyer, Managing Directormmoyer@ _______________________________i ZELSUVMI. Prescribing information. EPIH SPV, LLC. 2024. ii Browning JC, Enloe C, Cartwright M, et al. Efficacy and safety of topical nitric oxide-releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2022;158(8):871-878. iii Han H, Smythe C, Yousefian F, Berman B. Molluscum contagiosum virus evasion of immune surveillance: a review. J Drugs Dermatol. 2023;22(2): Neal Bhatia, Adelaide A Hebert, James Q Del Rosso. Comprehensive Management of Molluscum Contagiosum: Assessment of Clinical Associations, Comorbidities, and Management Principles. Journal of Clinical and Aesthetic Dermatology. 2023 Aug;16(8 Suppl 1):S12–S17.v Olsen JR, Gallacher J, Finlay A, Piguet V, Francis NA. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15:190-195 vi Molluscum contagiosum: overview. American Academy of Dermatology. Accessed December 9, 2024.
